651 related articles for article (PubMed ID: 31182537)
21. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.
Wang H; Xiao M; Chen SC; Kong F; Sun ZY; Liao K; Lu J; Shao HF; Yan Y; Fan H; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Xu YC
J Clin Microbiol; 2012 Dec; 50(12):3952-9. PubMed ID: 23035204
[TBL] [Abstract][Full Text] [Related]
22. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
23. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Chen TC; Chen YH; Chen YC; Lu PL
Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
[TBL] [Abstract][Full Text] [Related]
24. [Fluconazole and itraconazole susceptibility testing with clinical yeast isolates and algae of the genus Prototheca by means of the Etest].
Blaschke-Hellmessen R
Mycoses; 1996; 39 Suppl 2():39-43. PubMed ID: 9198743
[TBL] [Abstract][Full Text] [Related]
25. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
[TBL] [Abstract][Full Text] [Related]
26. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
Samra Z; Yardeni M; Peled N; Bishara J
Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
[TBL] [Abstract][Full Text] [Related]
27. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study.
Mokaddas EM; Al-Sweih NA; Khan ZU
J Med Microbiol; 2007 Feb; 56(Pt 2):255-259. PubMed ID: 17244809
[TBL] [Abstract][Full Text] [Related]
28. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.
Dannaoui E; Paugam A; Develoux M; Chochillon C; Matheron J; Datry A; Bouges-Michel C; Bonnal C; Dromer F; Bretagne S
Clin Microbiol Infect; 2010 Jul; 16(7):863-9. PubMed ID: 19778296
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Marco F; Pfaller MA; Messer S; Jones RN
Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
Lei J; Xu J; Wang T
J Mycol Med; 2018 Jun; 28(2):310-313. PubMed ID: 29685520
[TBL] [Abstract][Full Text] [Related]
31. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center.
Marcos-Zambrano LJ; Escribano P; Sánchez C; Muñoz P; Bouza E; Guinea J
Antimicrob Agents Chemother; 2014 Aug; 58(8):4565-72. PubMed ID: 24867979
[TBL] [Abstract][Full Text] [Related]
32. Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.
Hrabovský V; Takáčová V; Schréterová E; Pastvová L; Hrabovská Z; Čurová K; Siegfried L
Folia Microbiol (Praha); 2017 Nov; 62(6):525-530. PubMed ID: 28361459
[TBL] [Abstract][Full Text] [Related]
33. Antifungal susceptibility of 50 Candida isolates from invasive mycoses in Chile.
Silva V; Alvarado D; Diaz MC
Med Mycol; 2004 Jun; 42(3):283-5. PubMed ID: 15283244
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
[TBL] [Abstract][Full Text] [Related]
35. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute BMD method for non-Candida albicans and non-C. tropicalis bloodstream isolates from eleven tertiary hospitals in São Paulo state, Brazil.
Purisco SU; Martins MA; Szeszs MW; Castro e Silva DM; Pukinskas SR; Bonfietti LX; Baez AA; Melhem MS
FEMS Yeast Res; 2012 Dec; 12(8):890-6. PubMed ID: 22883021
[TBL] [Abstract][Full Text] [Related]
38. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.
Carrillo-Muñoz AJ; Quindós G; Ruesga M; Alonso R; del Valle O; Hernández-Molina JM; McNicholas P; Loebenberg D; Santos P
J Antimicrob Chemother; 2005 Mar; 55(3):317-9. PubMed ID: 15705637
[TBL] [Abstract][Full Text] [Related]
39. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
40. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
